Who is the CEO of AB Science S.A.?

Mr. Alain Moussy MBA is a business executive who currently serves as the CEO of AB Science S.A..

What is the Revenue Growth of AB Science S.A.?

Revenue growth data for AB Science S.A. is currently unavailable.

What is AB Science S.A. operating Margin?

AB Science S.A. operating margin is -847.50% which shows how much profit AB.PA earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does AB Science S.A. operate?

AB Science S.A. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is AB Science S.A. revenue growth?

Revenue growth data for AB Science S.A. is currently unavailable.

AB Science S.A.

AB.PA•EURONEXT

HealthcareDrug Manufacturers - Specialty & Generic

$1.46

$-0.00(-0.27%)

AB Science S.A. (AB.PA) Stock Overview

Explore AB Science S.A.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for AB.PAStats details for AB.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for AB.PAAnalyst Recommendations details for AB.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

CEO

Mr. Alain Moussy MBA

Employees

Headquarters

3, Avenue George V, Paris

Founded

2010